M3 receptor

Target id: 15

Nomenclature: M3 receptor

Family: Acetylcholine receptors (muscarinic)

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for M3 receptor in GtoImmuPdb

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 590 1q41-q44 CHRM3 cholinergic receptor muscarinic 3 29
Mouse 7 589 13 A1 Chrm3 cholinergic receptor, muscarinic 3, cardiac 62
Rat 7 589 17q12.1 Chrm3 cholinergic receptor, muscarinic 3 43,96
Previous and Unofficial Names
HM4 [74-75] | Chrm-3 | M3R | cholinergic receptor, muscarinic 3 | cholinergic receptor
Database Links
Specialist databases
GPCRDB acm3_human (Hs), acm3_mouse (Mm), acm3_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
Orphanet
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Structure of the M3 Muscarinic Acetylcholine Receptor
PDB Id:  4DAJ
Ligand:  tiotropium
Resolution:  3.4Å
Species:  Rat
References:  48
Natural/Endogenous Ligands
acetylcholine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
NNC 11-1585 Hs Full agonist 8.3 pKi 17
pKi 8.3 [17]
NNC 11-1607 Hs Full agonist 8.1 pKi 17
pKi 8.1 [17]
pentylthio-TZTP Hs Full agonist 8.1 pKi 41
pKi 8.1 [41]
NNC 11-1314 Hs Full agonist 7.1 – 7.7 pKi 17
pKi 7.1 – 7.7 [17]
xanomeline Hs Partial agonist 7.2 – 7.4 pKi 103,112
pKi 7.2 – 7.4 [103,112]
sabcomeline Hs Partial agonist 7.0 pKi 112
pKi 7.0 [112]
arecaidine propargyl ester Hs Full agonist 5.7 pKi 41
pKi 5.7 [41]
acetylcholine Rn Full agonist 5.6 pKi 16
pKi 5.6 [16]
arecoline Hs Full agonist 5.4 pKi 41
pKi 5.4 [41]
oxotremorine Hs Full agonist 5.3 pKi 41
pKi 5.3 [41]
McN-A-343 Hs Partial agonist 5.0 – 5.3 pKi 83
pKi 5.0 – 5.3 [83]
milameline Hs Partial agonist 5.1 pKi 112
pKi 5.1 [112]
oxotremorine-M Hs Full agonist 5.1 pKi 41
pKi 5.1 [41]
pilocarpine Hs Partial agonist 5.1 pKi 41
pKi 5.1 [41]
acetylcholine Hs Full agonist 4.5 – 5.4 pKi 16,41,52
pKi 4.5 – 5.4 [16,41,52]
methylfurmethide Hs Full agonist 4.6 pKi 41
pKi 4.6 [41]
bethanechol Hs Full agonist 4.2 pKi 41
pKi 4.2 [41]
carbachol Hs Full agonist 4.0 – 4.4 pKi 16,41,112
pKi 4.0 – 4.4 [16,41,112]
carbachol Rn Full agonist 4.2 pKi 16
pKi 4.2 [16]
furtrethonium Hs Full agonist 4.1 pKi 41
pKi 4.1 [41]
methacholine Rn Agonist 6.9 pEC50 73
pEC50 6.9 (EC50 1.2x10-7 M) [73]
pEC50 6.9 (EC50 1.2x10-7 M) [73]
(+)-aceclidine Hs Full agonist 5.7 pEC50 25
pEC50 5.7 [25]
(-)-aceclidine Hs Partial agonist 5.1 pEC50 25
pEC50 5.1 [25]
View species-specific agonist tables
Agonist Comments
Please consult references [10,26,54,83,101,110] for further details of the activity of some of the ligands in this list.
McN-A-343 has been found to be a partial agonist at the M3 receptor [83,101]. However, in reference [54] it was found to be inactive in a study of GTPase activation.
Oxotremorine has been found to be a full agonist [26,83,101] and a partial agonist [54,83] at the M3 receptor.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]tiotropium Hs Antagonist 10.7 pKd 85
pKd 10.7 [85]
[3H]QNB Hs Antagonist 10.4 pKd 75
pKd 10.4 (Kd 3.98x10-11 M) [75]
[3H]N-methyl scopolamine Rn Antagonist 10.0 pKd 16,101
pKd 10.0 [16,101]
[3H]N-methyl scopolamine Hs Antagonist 9.7 – 10.2 pKd 15-16,38-39,41-42,44,52
pKd 9.7 – 10.2 (Kd 2.2x10-10 – 6x10-11 M) [15-16,38-39,41-42,44,52]
[3H]darifenacin Hs Antagonist 9.5 pKd 89
pKd 9.5 (Kd 3.16x10-10 M) [89]
biperiden Hs Antagonist 8.4 pKd 6
pKd 8.4 (Kd 3.9x10-9 M) [6]
N-methyl scopolamine Hs Antagonist 10.4 pKi 21
pKi 10.4 [21]
tiotropium Hs Antagonist 9.5 – 11.1 pKi 20-21
pKi 9.5 – 11.1 [20-21]
umeclidinium Hs Antagonist 10.2 pKi 49,85
pKi 10.2 (Ki 6x10-11 M) [49,85]
propantheline Hs Antagonist 10.0 pKi 39
pKi 10.0 [39]
AE9C90CB Hs Antagonist 9.9 pKi 88
pKi 9.9 [88]
clidinium Hs Antagonist 9.6 pKi 21
pKi 9.6 [21]
ipratropium Hs Antagonist 9.3 – 9.8 pKi 21,38
pKi 9.3 – 9.8 [21,38]
scopolamine Hs Antagonist 9.4 pKi 39
pKi 9.4 [39]
atropine Hs Antagonist 8.9 – 9.8 pKi 11,21,38-39,75,89
pKi 8.9 – 9.8 [11,21,38-39,75,89]
4-DAMP Hs Antagonist 9.3 pKi 23
pKi 9.3 [23]
4-DAMP Rn Antagonist 9.2 pKi 43
pKi 9.2 [43]
dicyclomine Hs Antagonist 9.0 pKi 3
pKi 9.0 (Ki 9.3x10-10 M) [3]
atropine Rn Antagonist 8.7 – 9.3 pKi 16,43
pKi 8.7 – 9.3 [16,43]
hexocyclium Hs Antagonist 8.9 pKi 11
pKi 8.9 [11]
silahexocyclium Hs Antagonist 8.9 pKi 11
pKi 8.9 [11]
darifenacin Hs Antagonist 8.6 – 9.1 pKi 33,37-38,40,88
pKi 8.6 – 9.1 [33,37-38,40,88]
oxybutynin Hs Antagonist 8.8 – 8.9 pKi 19,40,88
pKi 8.8 – 8.9 [19,40,88]
tolterodine Hs Antagonist 8.4 – 8.5 pKi 33,88
pKi 8.4 – 8.5 [33,88]
UH-AH 37 Hs Antagonist 8.1 – 8.2 pKi 33,109
pKi 8.1 – 8.2 [33,109]
p-F-HHSiD Rn Antagonist 8.0 pKi 43
pKi 8.0 [43]
amitriptyline Hs Antagonist 7.9 pKi 90
pKi 7.9 (Ki 1.28x10-8 M) [90]
hexahydrosiladifenidol Hs Antagonist 7.7 – 8.0 pKi 11,27
pKi 7.7 – 8.0 [11,27]
solifenacin Hs Antagonist 7.7 – 8.0 pKi 40,88
pKi 7.7 – 8.0 [40,88]
hexahydrodifenidol Hs Antagonist 7.8 pKi 11
pKi 7.8 [11]
p-F-HHSiD Hs Antagonist 7.3 – 7.9 pKi 27,39
pKi 7.3 – 7.9 [27,39]
tropicamide Hs Antagonist 7.5 pKi 3
pKi 7.5 (Ki 3x10-8 M) [3]
dosulepin Hs Antagonist 7.4 pKi 90
pKi 7.4 (Ki 3.8x10-8 M) [90]
AQ-RA 741 Hs Antagonist 7.2 – 7.3 pKi 23,33
pKi 7.2 – 7.3 [23,33]
AFDX384 Hs Antagonist 7.2 pKi 23
pKi 7.2 [23]
himbacine Hs Antagonist 6.9 – 7.2 pKi 23,42,66
pKi 6.9 – 7.2 [23,42,66]
tripitramine Hs Antagonist 6.8 pKi 67
pKi 6.8 [67]
pirenzepine Rn Antagonist 6.7 pKi 43
pKi 6.7 [43]
pirenzepine Hs Antagonist 6.5 – 6.8 pKi 11,23,37,39,42,109
pKi 6.5 – 6.8 [11,23,37,39,42,109]
methoctramine Hs Antagonist 6.1 – 6.9 pKi 11,23,27,37,89
pKi 6.1 – 6.9 [11,23,27,37,89]
guanylpirenzepine Rn Antagonist 6.2 pKi 100
pKi 6.2 [100]
otenzepad Hs Antagonist 6.1 pKi 11
pKi 6.1 [11]
VU0255035 Hs Antagonist 6.1 pKi 86
pKi 6.1 [86]
otenzepad Rn Antagonist 6.0 pKi 43
pKi 6.0 [43]
muscarinic toxin 3 Hs Antagonist <6.0 pKi 42
pKi <6.0 [42]
lithocholylcholine Hs Antagonist 6.0 pKi 16
pKi 6.0 [16]
lithocholylcholine Rn Antagonist 6.0 pKi 16
pKi 6.0 [16]
muscarinic toxin 7 Hs Antagonist <5.0 pKi 69
pKi <5.0 [69]
ML381 Hs Antagonist <4.5 pKi 32
pKi <4.5 (Ki >3x10-5 M) [32]
aclidinium Hs Antagonist 9.8 pIC50 79
pIC50 9.8 (IC50 1.7x10-10 M) [79]
glycopyrrolate Hs Antagonist 9.6 pIC50 93
pIC50 9.6 (IC50 2.51x10-10 M) [93]
Description: Assay uses glycopyrronium bromide
solifenacin Hs Antagonist 6.9 pIC50 78
pIC50 6.9 (IC50 1.308x10-7 M) [78]
View species-specific antagonist tables
Antagonist Comments
Biperiden is an approved drug antagonist of muscarinic acetylcholine receptors. We have tagged the M1 subtype as the drug's primary target as affinity is 10-fold higher at this receptor subtype [6].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
alcuronium Hs Negative 5.8 pKd 41
pKd 5.8 [41]
vincamine Hs Neutral 5.7 pKd 41
pKd 5.7 [41]
WIN 51,708 Hs Negative 5.5 pKd 57
pKd 5.5 [57]
vinburnine Hs Neutral 5.2 pKd 41
pKd 5.2 [41]
Gö 7874 Hs Negative 5.1 pKd 56
pKd 5.1 [56]
WIN 62,577 Hs Positive 5.1 pKd 57
pKd 5.1 (Kd 7.94x10-6 M) [57]
strychnine Hs Negative 4.2 – 5.7 pKd 41,52
pKd 4.2 – 5.7 [41,52]
thiochrome Hs Neutral 4.4 pKd 53
pKd 4.4 [53]
N-benzyl brucine Hs Negative 3.8 pKd 55
pKd 3.8 [55]
N-benzyl brucine Hs Positive 3.8 pKd 55
pKd 3.8 [55]
brucine Hs Negative 3.6 – 4.0 pKd 41,55
pKd 3.6 – 4.0 [41,55]
N-chloromethyl-brucine Hs Positive 3.3 pKd 55
pKd 3.3 (Kd 5.012x10-4 M) [55]
brucine N-oxide Hs Neutral 2.5 pKd 55
pKd 2.5 [55]
brucine N-oxide Hs Positive 2.5 pKd 55
pKd 2.5 [55]
VU0119498 Hs Positive 5.2 pEC50 8
pEC50 5.2 (EC50 6.38x10-6 M) [8]
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  9,74
Tissue Distribution
Lung.
Species:  Human
Technique:  Radioligand binding.
References:  61
Ciliary muscle.
Species:  Human
Technique:  In situ hybridisation and Northern blotting.
References:  118
Esophageal smooth muscle.
Species:  Human
Technique:  Radioligand binding.
References:  80
Bladder.
Species:  Human
Technique:  RT-PCR.
References:  97
CNS: cerebral cortex, corpus striatum, hippocampus, thalamus, hypothalamus, midbrain, pons-medulla.
Species:  Mouse
Technique:  Radioligand binding.
References:  70
Intestinal smooth muscle.
Species:  Rat
Technique:  Radioligand binding.
References:  14
Heart: intrinsic neurons.
Species:  Rat
Technique:  in situ hybridisation.
References:  36
Gastric smooth muscle.
Species:  Rat
Technique:  RT-PCR.
References:  60
CNS: pons.
Species:  Rat
Technique:  Radioligand binding.
References:  4
CNS: basal forebrain, parabigeminal nucleus, pedunculopontine and laterodorsal tegmental nuclei, cranial nerve nuclei.
Species:  Rat
Technique:  in situ hybridisation.
References:  98
CNS: cerebral cortex, hippocampu, corpus striatum, olfactory tubercle, midbrain, pons-medulla, cerebellum.
Species:  Rat
Technique:  Immunoprecipitation.
References:  115
CNS: hippocampus.
Species:  Rat
Technique:  immunocytochemistry.
References:  59
CNS: limbic cortical regions, striatum, hippocampus, anterior thalamic nuclei, superior colliculus, pontine nuclei.
Species:  Rat
Technique:  immunocytochemistry.
References:  58
Vestibular system.
Species:  Rat
Technique:  RT-PCR.
References:  99
Salivary gland: striated and interlobular duct cells.
Species:  Rat
Technique:  Immunohistochemistry.
References:  87
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of PI hydrolysis in CHO cells transfected with the human M3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of PI hydrolysis.
References:  17
Measurement of ERK1/2 activity in CHO cells transfected with the human M3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in ERK1/2 activity.
References:  12
Measurement of IP3 levels in CHO cells transfected with the rat M3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Stimulation of IP3 accumulation.
References:  16
Measurement of IP1 levels in murine fibroblast cells (B82) transfected with the rat M3 receptor.
Species:  Rat
Tissue:  B82 cells.
Response measured:  Stimulation of IP1 accumulation.
References:  43
Measurement of cAMP and Ca2+ levels in rat parotid cells endogenously expressing the M3 receptor.
Species:  Rat
Tissue:  Parotid cells.
Response measured:  Inhibition of cAMP accumulation and stimulation of Ca2+ mobilisation.
References:  71
Measurement of IP levels in CHO cells transfected with the human M3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP accumulation.
References:  83,104
Measurement of IP levels in human right atrial slices.
Species:  Human
Tissue:  Atrial slices.
Response measured:  Stimulation of IP formation.
References:  111
Measurement of IP levels in isolated rat ventricular cardiomyocytes.
Species:  Rat
Tissue:  Isolated ventricular cardiomyocytes.
Response measured:  Stimulation of IP formation.
References:  81
Measurement of neuronal nitric oxide synthetase activity in CHO cells transfected with the M3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in NO synthetase activity.
References:  102
Measurement of ERK1/2 activity in COS-7 cells transfected with the human M3 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Increase in ERK1/2 activity.
References:  84
Measurement of ERK1/2 activity in human SK-N-BE2(C) cells endogenously expressing the M3 receptor.
Species:  Human
Tissue:  SK-N-BE2(C) cells.
Response measured:  Increase in ERK1/2 activity.
References:  46
Measurement of the effects of a ligand on the level, or rate, of binding of GTPγ35S to membranes.
Species:  Human
Tissue:  CHO cells.
Response measured:  The binding of GTPγ35S to G proteins coupled to the receptor.
References:  5,51-54,56-57
Measurement of the effects of a ligand on the rate of hydrolysis of GTP by G proteins in membranes.
Species:  Human
Tissue:  CHO cell membranes.
Response measured:  Generation of 32Pi from [γ-32P]GTP.
References:  54
Physiological Functions
Vasodilation.
Species:  Rat
Tissue:  Thoracic aortic rings.
References:  45
Vasodilation
Species:  Mouse
Tissue:  Thoracic aortic rings.
References:  45
Stimulation of pancreatic insulin and glucagon release.
Species:  Mouse
Tissue:  In vivo.
References:  22
Bronchoconstriction.
Species:  Rat
Tissue:  Isolated lung.
References:  77
Modulation of salivary gland function.
Species:  Rat
Tissue:  In vivo.
References:  95
Modulation of excitatory transmission.
Species:  Rat
Tissue:  Mesencephalic slices.
References:  35
Gastric acid secretion.
Species:  Rat
Tissue:  Gastric parietal cells.
References:  76
Modulation of insulin secretion.
Species:  Rat
Tissue:  Isolated pancreatic islets.
References:  82
Vasodilation.
Species:  Rat
Tissue:  Pulmonary artery.
References:  65
Stimulation of urination.
Species:  Rat
Tissue:  In vivo.
References:  47
Contraction.
Species:  Human
Tissue:  Urinary bladder detrusor muscle.
References:  18
Contraction.
Species:  Rat
Tissue:  Urinary bladder detrusor muscle.
References:  72
Contraction.
Species:  Human
Tissue:  Esophageal smooth muscle.
References:  80
Contraction.
Species:  Rat
Tissue:  Ileum.
References:  14
Physiological Consequences of Altering Gene Expression
M3 receptor knockout mice exhibit impaired salivation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  68
M3 receptor knockout mice exhibit impaired gastric acid secretion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1-2
M3 receptor knockout mice exhibit altered ventilatory pattern and chemosensitivity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  7
M3 receptor knockout mice exhibit abolished agonist-induced or vagally-stimulated bronchoconstriction in vivo.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  28
M3 receptor knockout mice exhibit abolished agonist-induced PLC activation and insulin secretion from pancreatic islets.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  116
M3 receptor knockout mice show reduced adiposity and serum insulin and leptin levels, and exhibit reduced food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  114
Lung slices from M3 receptor knockout mice exhibit reduced agonist-induced bronchoconstriction compared to wild-type mice.
This bronchoconstriction is completely abolished in M2/M3 double knockout mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  94
Isolated coronary arteries and aortic rings from M3 receptor knockout mice exhibit a reduction in agonist-induced dilation compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  50
M3 receptor knockout mice exhibit alterations in paradoxical sleep.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  34
M3 receptor knockout mice exhibit growth retardation, increased pupil size and reduced salivary secretion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  63
Striatal slices from M3 receptor knockout mice exhibit an increase in muscarinic agonist-induced potentiation of dopamine release.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  117
M3 receptor knockout mice exhibit abolished agonist-induced pancreatic insulin and glucagon release as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  22
M3 receptor knockout mice exhibit reduced gastric pepsinogen secretion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  113
Thoracic aortic rings from M3 receptor knockout mice exhibit reduced agonist-induced relaxation compared to those from wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  45
Transgenic mice overexpressing the M3 receptor in pancreatic β-cells exhibit increased glucose tolerance and insulin release. They are resistant to diet-induced glucose intolerance and hyperglycemia.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  31
Mice that selectively lack the M3 receptor in pancreatic β-cells exhibit decreased glucose tolerance and impaired insulin release.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
M3 receptor knockout mice express an increase in basal and total energy expenditure.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  30
Smooth muscle preparations (gallbladder, urinary bladder, stomach fundus, trachea, ileum) from M3 receptor knockout mice exhibit reduced agonist-induced contractions compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  24,63,91-92
Smooth muscle preparations (gallbladder, urinary bladder, stomach fundus, trachea) from M3 receptor knockout mice exhibit reduced agonist-induced contractions compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  63,91-92
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0004994 abnormal brain wave pattern PMID: 16110248 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac
MGI:88398  MP:0001663 abnormal digestive system physiology PMID: 11959688 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0003194 abnormal frequency of paradoxical sleep PMID: 16110248 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0005085 abnormal gallbladder physiology PMID: 11961069 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002078 abnormal glucose homeostasis PMID: 11242080 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
B6.129X1-Chrm3
MGI:88398  MP:0002503 abnormal histamine physiology PMID: 15691866 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ
MGI:88398  MP:0002945 abnormal inhibitory postsynaptic currents PMID: 12859343 
Chrm1tm1Kano|Chrm3tm1Mmt Chrm1tm1Kano/Chrm1tm1Kano,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88396  MGI:88398  MP:0002945 abnormal inhibitory postsynaptic currents PMID: 12859343 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac
MGI:88398  MP:0002133 abnormal respiratory system physiology PMID: 11959688 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ
MGI:88398  MP:0005310 abnormal salivary gland physiology PMID: 15146045 
Chrm1tm1Kano|Chrm3tm1Mmt Chrm1tm1Kano/Chrm1tm1Kano,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88396  MGI:88398  MP:0005310 abnormal salivary gland physiology PMID: 15146045 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000538 abnormal urinary bladder morphology PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac
MGI:88398  MP:0010386 abnormal urinary bladder physiology PMID: 11959688 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0001945 bronchoconstriction PMID: 14645675 
Chrm2tm1Jwe|Chrm3tm1Jwe Chrm2tm1Jwe/Chrm2tm1Jwe,Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S4/SvJae * 129S6/SvEvTac * CF-1
MGI:88397  MGI:88398  MP:0001945 bronchoconstriction PMID: 14645675 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0001265 decreased body size PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0005534 decreased body temperature PMID: 11242080 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0001262 decreased body weight PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0001262 decreased body weight PMID: 11242080  15220195 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
129S6/SvEvTac-Chrm3
MGI:88398  MP:0001262 decreased body weight PMID: 11242080 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac
MGI:88398  MP:0001262 decreased body weight PMID: 11959688 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002696 decreased circulating glucagon level PMID: 15220195 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0005560 decreased circulating glucose level PMID: 15220195 
Chrm3tm2.1Jwe|Tg(Alb-cre)21Mgn Chrm3tm2.1Jwe/Chrm3tm2.1Jwe,Tg(Alb-cre)21Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N
MGI:2176226  MGI:88398  MP:0005560 decreased circulating glucose level PMID: 19752163 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002727 decreased circulating insulin level PMID: 11242080  15220195 
Chrm3+|Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3+
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002727 decreased circulating insulin level PMID: 15220195 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0005668 decreased circulating leptin level PMID: 11242080 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002644 decreased circulating triglyceride level PMID: 11242080 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
B6.129X1-Chrm3
MGI:88398  MP:0000505 decreased digestive secretion PMID: 15691866 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0003910 decreased eating behavior PMID: 11242080 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0002711 decreased glucagon secretion PMID: 15220195 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0009283 decreased gonadal fat pad weight PMID: 11242080 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
129S6/SvEvTac-Chrm3
MGI:88398  MP:0009283 decreased gonadal fat pad weight PMID: 11242080 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0003059 decreased insulin secretion PMID: 15220195 
Chrm3tm2Jwe|Tg(Ins2-cre)25Mgn Chrm3tm2Jwe/Chrm3tm2Jwe,Tg(Ins2-cre)25Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * DBA
MGI:2176225  MGI:88398  MP:0003059 decreased insulin secretion PMID: 16753580 
Chrm3+|Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3+
involves: 129S6/SvEvTac * C57BL/6J
MGI:88398  MP:0003059 decreased insulin secretion PMID: 15220195 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ
MGI:88398  MP:0000623 decreased salivation PMID: 15146045 
Chrm1tm1Kano|Chrm3tm1Mmt Chrm1tm1Kano/Chrm1tm1Kano,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88396  MGI:88398  MP:0000623 decreased salivation PMID: 15146045 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000623 decreased salivation PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0005591 decreased vasodilation PMID: 15130910 
Chrm2tm1Minm|Chrm3tm1Mmt Chrm2tm1Minm/Chrm2tm1Minm,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88397  MGI:88398  MP:0000539 distended urinary bladder PMID: 12486155 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000539 distended urinary bladder PMID: 10944224 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000519 hydronephrosis PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0009454 impaired contextual conditioning behavior PMID: 20439723 
Chrm3tm1Abt Chrm3tm1Abt/Chrm3tm1Abt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0009454 impaired contextual conditioning behavior PMID: 20439723 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000741 impaired contractility of detrusor smooth muscle PMID: 10944224 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ
MGI:88398  MP:0000742 impaired contractility of ileal smooth muscle PMID: 12486155 
Chrm2tm1Minm|Chrm3tm1Mmt Chrm2tm1Minm/Chrm2tm1Minm,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88397  MGI:88398  MP:0000742 impaired contractility of ileal smooth muscle PMID: 12486155 
Chrm3tm1Mmt Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88398  MP:0000742 impaired contractility of ileal smooth muscle PMID: 10944224 
Chrm3tm1Jwe Chrm3tm1Jwe/Chrm3tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88398  MP:0009456 impaired cued conditioning behavior PMID: 20439723 
Chrm3tm1Abt Chrm3tm1Abt/Chrm3tm1Abt
involves: 129X1/SvJ * C5